Edit Entry | Edit CV

Constance E. Brinckerhoff, PhD

Emeritus Professor of Medicine


Smith College, BA
SUNY - Buffalo, PHD
SUNY - Buffalo, MA

Molecular and Cellular Biology Graduate Programs

NIH Biosketch

Contact Information

Dartmouth Medical School
HB 7936
Lebanon NH 03756

Phone: 603-653-9957
Fax: 603-653-9952
Email: brinckerhoff@dartmouth.edu

Professional Interests

Research focuses on the molecular and cellular mechanisms by which the Matrix Metalloproteinases (MMPs), enzymes that degrade the extracellular matrix at neutral pH, facilitate the invasive and metastatic behavior of tumor cells. In most normal cells, constitutive expression of MMPs is low, but increases in response to cytokines and growth factors. In some tumors (e.g., breast cancer and melanoma), however, MMP expression is constutively high, and the high expression enhances their invasiveness. This lab is using a novel invasion assay to monitor the invasion of tumor cells through the extracellular matrix and to document the efficacy of novel agents that suppress MMPs to also suppress invasion and metastasis.

Grant Information

AR-26599-28. Regulation of Collagenase Gene Expression
CA-77267-07. Invasive Behavior of Tumor cells Producing Collagenase-1

Selected Publications


Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses.
Lo JA, Kawakubo M, Juneja VR, Su MY, Erlich TH, LaFleur MW, Kemeny LV, Rashid M, Malehmir M, Rabi SA, Raghavan R, Allouche J, Kasumova G, Frederick DT, Pauken KE, Weng QY, Pereira da Silva M, Xu Y, van der Sande AAJ, Silkworth W, Roider E, Browne EP, Lieb DJ, Wang B, Garraway LA, Wu CJ, Flaherty KT, Brinckerhoff CE, Mullins DW, Adams DJ, Hacohen N, Hoang MP, Boland GM, Freeman GJ, Sharpe AH, Manstein D, Fisher DE
Sci Transl Med. 2021 Feb 17;13(581) doi: 10.1126/scitranslmed.abd8636.
PMID: 33597266

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Bellmann L, Cappellano G, Schachtl-Riess JF, Prokopi A, Seretis A, Ortner D, Tripp CH, Brinckerhoff CE, Mullins DW, Stoitzner P
Int J Cancer. 2020 Mar 1;146(5):1409-1420. doi: 10.1002/ijc.32777. Epub 2019 Dec 4.
PMID: 31702822

Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?
Brinckerhoff CE
J Cell Physiol. 2017 Oct;232(10):2674-2678. doi: 10.1002/jcp.25796. Epub 2017 Mar 6.
PMID: 28078710

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS
Melanoma Res. 2016 Jun;26(3):223-35. doi: 10.1097/CMR.0000000000000244.
PMID: 26974965

What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib?
Brinckerhoff CE
Melanoma Manag. 2016 Mar;3(1):5-8. doi: 10.2217/mmt.15.36. Epub 2016 Feb 18.
PMID: 30190867

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE
Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.
PMID: 25989506

CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.
Jenkins MH, Brinckerhoff CE, Mullins DW
PLoS One. 2015;10(3):e0121140. doi: 10.1371/journal.pone.0121140. Epub 2015 Mar 23.
PMID: 25798946

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.
Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ
Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.
PMID: 25183499

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.
Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE
Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6.
PMID: 24460976

Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.
Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE
J Cell Physiol. 2013 Apr;228(4):773-80. doi: 10.1002/jcp.24225.
PMID: 23001823

View more publications on PubMed